Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Clinical trial NCT06057402 · RECRUITING

Trial details

NCT number: NCT06057402
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2023-10-03
Primary completion: 2032-02-22
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.